Drug-Eluting Stent

Long-term outcomes of PCI with a sirolimus-eluting stent vs. CABG for unprotected left main CAD.

Patients who underwent coronary revascularization with a bioresorbable polymer sirolimus-eluting stent had significantly lower rates of target vessel MI, late/very late stent thrombosis and clinically driven target lesion revascularization compared with those who underwent the procedure with a durable polymer everolimus-eluting stent, according to 3-year data from the BIOFLOW V trial presented at Cardiovascular Research Technologies.

A recent meta-analysis detecting a signal of harm at 1 year in patients with below-the-knee lesions treated with paclitaxel-coated balloons is flawed and should not impact clinical practice, a speaker said at the International Symposium on Endovascular Therapy.

Outcomes at 2 years were similar for patients who underwent PCI with a ridaforolimus-eluting stent compared with a zotarolimus-eluting stent, according to a pooled analysis of two randomized trials published in JACC: Cardiovascular Interventions.

Healio and Cardiology Today present meeting highlights from VIVA 19 in Las Vegas. Top stories included the latest from the IMPERIAL head-to-head comparison of two peripheral drug-eluting stents, a low-dose paclitaxel-coated balloon, new advances for patients with critical limb ischemia and more.

LAS VEGAS — A bioresorbable scaffold was shown to be safe and effective for treatment of below-the-knee lesions in two studies presented at VIVA 19.

LAS VEGAS — A sirolimus-coated balloon for treatment of peripheral artery disease was associated with positive outcomes at 2 years, according to new data from the SELUTION study presented at VIVA 19.

LAS VEGAS — A peripheral drug-eluting stent with a polymer coating conferred lower rates of target lesion revascularization compared with a peripheral DES without a polymer coating, according to 2-year results from the IMPERIAL trial.

LAS VEGAS — There were no significant differences in mortality at 5 years between patients with peripheral artery disease assigned a drug-eluting stent and those assigned a bare-metal stent or percutaneous transluminal angioplasty, according to new data presented at VIVA 19.

Confirming previously presented results, ticagrelor monotherapy after 1 month of dual antiplatelet therapy was similar to a standard DAPT regimen for the prevention of ischemic events without differences in bleeding following drug-eluting coronary stenting.